Ublituximab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 455, doi. 10.1007/s40265-023-01854-z
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 5
Results: 9
1
2
Authors' Reply to Huang and Zhang: Comment on "Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study".
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
3
Comment on: "Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study".
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
4
Bexagliflozin: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 447, doi. 10.1007/s40265-023-01848-x
- By:
- Publication type:
- Article
5
Teplizumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 439, doi. 10.1007/s40265-023-01847-y
- By:
- Publication type:
- Article
6
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 367, doi. 10.1007/s40265-023-01843-2
- By:
- Publication type:
- Article
7
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 403, doi. 10.1007/s40265-023-01841-4
- By:
- Publication type:
- Article
8
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 389, doi. 10.1007/s40265-023-01838-z
- By:
- Publication type:
- Article
9
Aspirin for the Prevention of Early and Severe Pre-Eclampsia Recurrence: A Real-World Population-Based Study.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 429, doi. 10.1007/s40265-023-01842-3
- By:
- Publication type:
- Article